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Abstract
Background: Diffusion of new drugs in the health care market affects patients’ access to new treatment options
and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs),
diffused in the health care market in Taiwan.
Methods: Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug
penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan’s National
Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion
parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration
(maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were
estimated for analyses on the diffusion parameters.
Results: Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the
new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%
CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%
CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital’s prior anti-
diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had
adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more
quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50).
Conclusions: Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The
TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription
volume of Anti-diabetic drugs.
Background
New medical technology improves quality of life and
extends longevity, but it also accounts for most of the
growth in health care spending [1,2] and influences the
health care market by shifting demand [3]. The rate at
which a new medical technology is adopted by care pro-
viders (i.e., the speed of diffusion) affects the short-term
and medium-term benefits and costs. Understanding the
diffusion of technology and its impact on the overall
health care expenditure is essential to health care finan-
cing and insurance coverage.
Diffusion is the informal process by which innovations
spread to members of a social system [4]. It is deter-
mined by the attributes of the innovation itself, commu-
nication over time, and attributes of the social system.
In Rogers’ (1962) diffusion theory, a continuum of cul-
tural norms from traditional to modern is proposed to
explain how a given social system responds to a new
idea across space and time [5]. The social system’s
adoption of an innovation is determined by individuals’
knowledge, attitudes, and behavior toward the innova-
tion [5]. It may be driven by information transfers [6],
normative pressures [7], and network effects [8]. Rogers
subcategorized members of a social system into the
innovators, early adopters, early majority, late majority,
and laggards.
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the number of adopters into his model, Bass found that
the spread of new product information resembled the
spread of contagion as described in epidemiology and
that was distributed through social forces to potential
buyers who adopt the new product over time [9,10].
Researchers have investigated the diffusion or adop-
tion patterns of high-cost new medical technologies
such as computer topography (CT) scans [11], magnetic
resonance imaging (MRI) machines [11-14], neonatal
intensive care units (NICU) [15], laparoscopic instru-
ments [16-21], and technologies for specific diseases or
surgery [22-24]. Diffusion of the expensive technologies
is largely influenced by their characteristics, profitability,
prestige value, familiarity, and investment costs [25].
Other factors include organizational characteristics of
the adopter, insurance reimbursement, public regula-
tions, malpractice concerns, competitive or cooperative
interactions among providers, and demographics [26].
However, the most important factors for acquisition of
new technology and frequency of use are insurance, reg-
ulation, and provider interaction [26].
Large quantities of less expensive items routinely pur-
chased by hospitals may add up to a greater impact on
overall costs than expensive but less utilized items [27].
Prescription drugs are one such category of items.
Although new drugs sometimes reduce the total cost of
treatment [28], replacing older, cheaper drugs by newer,
more expensive drugs accounts for a substantial portion
of the rise in health care expenditures [29] and deserves
further study.
Few studies have examined the diffusion of new drugs
[24,30-32] and the impact on health care market. Past
studies have focused on pricing and quantity of pharma-
ceuticals, the competition between brand name products
and generics [33-36], the effect of generics on the price
and market share of brand name products [37-47], as
well as the effect of new drug diffusion on the quality
differentiation and marketing efforts [34,48]. In contrast
to macro-market analyses, little research has been con-
ducted on new drug diffusion patterns in hospitals. Hos-
pitals vary in size, policies, production function, market
power, and input factor costs, all characteristics that can
contribute to new drug diffusion. Thiazolidinediones
(TZDs) are oral medications that increase insulin sensi-
tivity and cardiovascular complications in patients with
type 2 diabetes mellitus [49]. Rosiglitazone and pioglita-
zone are two of such agents approved by the U.S. Food
and Drug Administration in 1999. Their use spread
quickly throughout the U.S, where their use to treat
type 2 diabetes increased from 2.2% in 1997 to 5.4% in
2001 [50]. In 2001, outpatient prescriptions of oral anti-
diabetic agents totaled 91.8 million [51]. In Taiwan,
BNHI data indicated that the total annual prescriptions
for both TZDs increased from 1.42% of all anti-diabetic
agents in 2001, the year the BNHI first listed them in
the national formulary for reimbursement, to 10.78% in
2003 [52].
This study analyzed nationwide prescription claims
data to characterize how a new DM drug (TZD) is
adopted and utilized in different hospitals how soon the
hospital starts prescribing TZD, how fast the prescrip-
tion grows, and to what extent the number of prescrip-
tions increases. We also sought to investigate whether
hospital characteristics can explain the variation of
diffusion.
Characteristics of health care and the pharmaceutical
market in Taiwan
In Taiwan, a national health insurance (NHI) program
covers the healthcare of over 99% of Taiwan’sc i t i z e n s .
It provides comprehensive health coverage, including
prescribed medications. Hospitals in Taiwan provide
both inpatient and outpatient services. Under NHI,
there is no gatekeeper or strict referral system, and thus
p a t i e n t sa r ef r e et oc h o o s et h eh e a l t hc a r ep r o v i d e r .
Because outpatients are usually the hospitals’ main
source for possible inpatients, hospitals are often moti-
vated to compete for outpatient patients with clinics.
Drugs in Taiwan are prescribed by physicians and are
dispensed by hospitals or clinics. In 2007, 67.29% of
NHI total medical care expenses were devoted to outpa-
tient care, 30.14% being devoted to pharmaceuticals
[53]. Hospitals, however, claimed 61.18% of the total
NHI outpatient care expense and 70.21% of the outpati-
ent pharmaceutical expenses [53]. In Taiwan, hospital
behavior varies by hospital accreditation level, hospital
capacity and organization. Hospitals accredited as medi-
cal centers usually have more than a thousand beds,
while those accredited as regional and district hospitals
have more than a hundred. Medical centers see more
than four times and 27 times the number of DM
patients on an outpatient basis than regional and district
hospitals, respectively [54]. They have also been found
to be early adopters of TZD and found to have higher
penetration rates than hospitals at other accreditation
levels [54].
Methods
Study design
The entries of rosiglitazone and pioglitazone into Taiwan
were marked by their inclusion in the BNHI official list
of pharmaceuticals for reimbursement on March 1, 2001
and February 2, 2002, respectively. We combined both
drugs into one drug class for analyses. In this study, each
hospital was treated as a small market, a microcosm of a
larger market. We first classified 580 hospitals into three
groups: innovators and early adopters (top 0-16%), early
Wen et al. BMC Health Services Research 2011, 11:21
http://www.biomedcentral.com/1472-6963/11/21
Page 2 of 13majority (17%-50%), late majority and laggards (51%-
100%). Because 35% did not adopt the drugs, we com-
bined the late majority and laggards into one group. We
also examined how soon these hospitals started prescrib-
ing TZD after the BNHI listed these drugs. Due to the
need for sufficient observations for each hospital, we
identified 327 long-term adopters, hospitals that had pre-
scribed TZDs for more than 12 months, for our analysis
of the diffusion once they had adopted TZDs. We exam-
ined how fast the prescription numbers increased and
when the prescription numbers reached a peak from
March 1, 2001 (when they were included in the BNHI
list) to December 31, 2005.
To do this, we used monthly outpatient insurance
claims, submitted by each hospital, to create monthly
trends in the prescription of anti-diabetic drugs for each
hospital. Monthly insurance claims can be used to chart
diffusion, characterized by time to first prescription for
a TZD (TA), diffusion speed by month (CR.TDDD),
peak use (Max.TDDD), and plateau (Diff_Plt). As shown
in Figure 1, the first use of a TZD in hospitals generally
started later than the date the drugs were listed on the
BNHI formulary.
Sample Definition
This study focused on all hospitals (n = 651) treating
patients with Type 2 diabetes (ICD9CM = 250.X2) in
Taiwan between 2000 and 2005. We did not include
clinics because they usually lacked economies of scale
a n dw e r em o r el i k e l yt oh a v ec o n t r a c t sw i t has p e c i f i c
pharmaceutical company or limited number of phar-
maceutical companies, and would, therefore, not be
representative of competitive markets for pharmaceu-
tical companies. We further excluded 71 hospitals
with monthly prescriptions of anti-diabetes drugs
fewer than four. These hospitals were different from
the hospitals included in the study in terms of
economies of scale, prescription volume and prescrip-
tion pattern [54]. We were left with 580 hospitals to
s t u d yt i m et oT Z Da d o p t i o n .T hey were classified into
(1) innovoators or early adopters (n = 93), (2) early
majority (n = 197) and (3) late majority and laggards
(n = 290). Because of considerations regarding scale,
we focused our attention on 327 long-term adopters,
hospitals which had prescribed TZDs for more than
twelve months. The other 253 hospitals were short-
term adopters or non-adopters, and they were
excluded from analysis for the diffusion pattern after
adoption. These hospitals were different from those
long-term adopters with regard to accreditation level
and ownership (Table 1). They tended to have higher
pharmaceutical concentration (Herfindahl-Hirschman
Index), fewer physicians on staff, and lower volumes of
Defined Daily Doses (DDD) of diabetic prescriptions.
They also started prescribing TZDs approximately
three years after the entry of new drug, far later than
those included in analysis (mean, 15 months).
Defined daily doses (DDD), a WHO statistical mea-
sure of drug consumption, are used to standardize
the comparative usage of various drugs between
themselves or between different health care environ-
ments. A DDD is the assumed average maintenance
dose per day for a drug used for its main indication
in adults [55].
Variables
Based on Roger’s diffusion theory, hospitals could classi-
fied by when they adopted the drugs: (1) innovators and
early adopters (first 16% percentile), (2) early majority
(17% to 50% percentile), and (3) late majority and lag-
gards (51% to 100% percentile). Market penetration was
measured by the total number of TZD prescriptions
(TDDD) in a hospital (i) within a given month (t). Based
on the conceptual diffusion model described in Diagram
1, we used three key parameters to characterize the dif-
fusion pattern of TZD in a hospital: (1) adoption time
(TA), defined as the number of months between March
1, 2001 (the date when rosiglitazone was added to the
BNHI reimbursement list) and the first time the hospital
filed a reimbursement claim for a TZD prescription;
(2) peak use of TZD prescriptions (Max.TDDD), defined
as the highest number of TZD prescription claims in a
month; and (3) penetration speed (CR.TDDD), defined
as the monthly rate of increase of TZD prescription
claims since the hospital made its first claim and calcu-
lated as Max.TDDD/(TM-TA)w h e r eTM is the time of
TZD peak use.
Independent variables included each hospital’s accredi-
tation level (AL), ownership (OWN), and the BNHI
region (REG) to which it belongs. Data were collected
from BNHI database of health care institutions. Taiwan’s
Max.TDDD
TA
CR.TDDD
Diff_Plt
TM
month
Figure 1 The conceptual diagram of diffusion pattern of new
drug TZD in each hospital TA: time to first prescription for a
TZD TM: time of peak prescription of TZD CR.TDDD: diffusion
speed by month Max.TDDD: peak use of TZD Diff_Plt: plateau.
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(AL): medical center, regional hospital, district hospital,
and physician’s clinic. As mentioned earlier, clinics were
not included in our study. Ownership (OWN) types
included public, private, and non-profit. There are six
BNHI regions (REG) including the Taipei, Northern,
Central, Southern, Kao-Ping, and Eastern regions. Two
economic factors at each hospital were considered: (1)
the total number of physicians who prescribed TZDs
(NDr) each month and (2) economic scale, defined as
Table 1 Characteristics of adopters
Long-term
adopters
Short-term
adopters
Non-
adopters
P-value
N% N % N %
Total 327 100 48 100 205 100
Accreditation level
Medical Center 18 5 0 0 1 0
Regional Hospital 68 21 2 4 8 4
District Hospital 241 74 46 96 196 96 0.0000
4
Ownership
Public Hospital 67 20 7 15 17 8
Non-profit Hospital 65 20 3 6 4 2
Private Hospital 195 60 38 79 184 90 0.0000
4
BNHI Regions
Taipei 78 24 12 25 26 13
Northern 49 15 6 12 23 11
Central 81 25 5 10 40 20
Southern 49 15 9 19 40 20
Kao-Ping 59 18 14 29 72 35
Eastern 11 3 2 5 4 1 0.0003
4
mean Std mean Std mean Std
Herfindahl-Hirschman Indexes
1 (HHI) 0.339 0.137 0.45 0.180 0.57 0.223 0.0000
5
Number of doctors who prescribed TZD drug 34.02 66.97 4.86 5.16 - -
Initial TZD use after TA (month) 15.19 11.61 36.79 16.00 - -
Total DDD of DM
2 (DDD) 37917.47 77383.05 8468 12601 2243 3958 0.0000
5
mean Std
Maximum monthly TZD penetration
3 0.117 0.067 - - - -
Time between initial adoption and the maximum
penetration (month)
26.14 13.16 - - - -
mean Std
Peak use (maximum monthly prescription of TZD in DDD) 6970.01 12678.72 - - - -
The time between initial adoption to the maximum
prescription of TZD (month)
27.02 13.17 - - - -
Prescription Speed (monthly growth on TZD prescription
in DDD)
252.65 374.31 - - - -
Maximum prescription in DDD
25% quantile 924.83 - - - -
50% quantile 2488 - - - -
75% quantile 6454.83 - - - -
Rate of penetration
25% quantile 39.99 - - - -
50% quantile 111.22 - - - -
75% quantile 293.97 - - - -
1: concentration index for hospitals in February, 2001.
2: the total DDD of DM drugs in February, 2001.
3: Maximum TZDs DDD/all DM drugs DDD.
4: c
2 test.
5: one-way ANOVA.
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prescribed in February, 2001 and denoted as log(TDDD.
DM)) in the statistical models.
Another important factor is the pharmaceutical con-
centration index (HHI_DDD) of a hospital prior to the
new drug entry, reflecting the pre-existing market share
structure of anti-diabetic drugs. It was hypothesized that
the new drug would confront stronger entry barriers in a
less competitive market when the pre-existing use of
anti-diabetic drugs was heavily dominated by certain
drugs. Here we used Herfindahl-Hirschman Index (HHI)
to measure the concentration of anti-diabetic drugs mar-
ket share structure within a hospital before TZDs were
made available. HHI, a concentration index, is commonly
used by competition economists and competition autho-
rities to measure market concentration. It is used to
show the extent of market control of the largest firms in
t h ei n d u s t r ya n dt oi l l u s t r a t et h ed e g r e et ow h i c ha n
industry is oligopolistic. It is defined as the sum of the
squares of the market shares of the 50 largest firms (or
summed over all the firms if there are fewer than 50)
within the industry, where the market shares are
expressed as fractions. The result is proportional to the
average market share, weighted by market share. As
such, it can range from 0 to 1.0, moving from a huge
number of very small firms to a single monopolistic pro-
ducer. Increases in the Herfindahl index generally indi-
cate a decrease in competition and an increase of market
power, whereas decreases indicate the opposite.
In our study, to calculate HHI_DDD, all 140 anti-dia-
b e t i cd r u g so nt h eN B H Il i s tw e r ef i r s tr a n k e db yt h e i r
market share. The top 56 drugs accounted for 99% of
the diabetic drug market and were individually consid-
ered as separate items. The remaining 84 brands
accounted for only one percent of the market share and
were combined into one item for a total of 57 drug
items. For each hospital i in month t,
HHI S DDD it itj
j
=∑ _
2
,w h e r eS DDDitj _
2 is the total
DDD share of drug item j summed over all of the drug
items in the hospital. In the empirical analysis, we will
multiply HHI by 100 for the estimation purposes.
Empirical models
Multinomial Logistic Regression for Different Adopters (n = 580)
Hospitals characterized by the likelihoods they would
adopt TZDs–innovators and early adopters (i = 2), early
majority (i = 3) and late majority and laggards (i = 1)
–were modeled by a multinomial logistic regression
with adjustments for hospital covariates:
Pr
exp )
exp ( )
(y=i)=
 (X
 X
T
m=2
T
i
m
Y
Y 1
3 +Σ
where Yi,i = 2,3 is the vector of regression parameters,
all parameters in g1 are set to be zero and X is the vec-
tor of independent variables (includes OWN, REG,
100×HHI and log(TDDD.DM)).
Survival Analysis for the Adoption of TZD (n = 580)
A Cox proportional hazards model was used to evaluate
the association between hospital characteristics and
adoption of TZD:
h TA h (TA)exp(Z
T () ) = 0 
where h0(TA) denotes the baseline hazard function,
and where a is the vector of regression parameters and
Z (includes OWN, REG, HHI and AL) is the vector of
independent variables. Stratified Cox proportion hazards
model was applied based on hospital accreditation level,
ownership, and region. The results from stratified Cox
proportion hazard model are presented in graphs.
Quantile Regressions for Peak Use and Penetration Rate
(n = 327)
To test the association between hospital characteristics
and peak use and rate of TZD penetration, we used the
quantile regression model as proposed by Koenker and
Bassett [56] to estimate conditional quantile functions,
where the quantiles of a response variable’s distribution
are specified as functions of observed covariates.
For hospital i, its TZD peak use and penetration rate
are denoted by Max.TDDDi and CR.TDDDi, respec-
tively. The quantile regression model pertaining to the
θth quantile can be expressed as the following:
Q Max TDDD X X ii i  
11 11 (. | )
’ =
and
Q CRTDDD X X ii i  
22 22 (. | )
’ =
where bθ1 and bθ2 are the vectors of coefficients, and
X1i and X2i the design matrices of the independent
variables for Max.TDDDi and CR.TDDDi, respectively.
X1i includes hospital characteristics of TA, log (TDDD.
DM), NDr, CR.TDDD, AL, OWN, and REG. X2i
includes hospital characteristics of TA, log (TDDD.
DM), HHI, NDr, AL, OWN, and REG. Qθ1(Max.TDDDi
X1i); Qθ2(CR.TDDDi|X2i) is the conditional quantile
functions of Max.TDDDi and CR.TDDDi and θi (i =
1,2) is the quantile (25%, 50% and 75%). The kth ele-
ment of vector bθ1 and bθ2 represents the marginal
effect of the kth


1
1 1
1
 k
ii
ik
Q Max TDDD X
X
=
∂
∂
(. | )
and
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where bθ1k is the marginal change in the θth condi-
tional quantile as a result of a change in X1ik. bθ1k , mar-
ginal effect, varies over the different quantiles. For a
given set of Xji, we estimate a set of coefficents {bθj, θj=
0.25, 0.5, 075, j = 1,2}.
Results
Table 1 shows the characteristics of the 580 hospitals:
long-term adopters (n = 327), short-term adopters (n =
48) and non-adopters (n = 205). Most of the hospitals
were district hospitals (n = 241, 74% long-term adopters;
n = 46, 96% short-term adopters; n = 196, 96% non-
adopters) and privately owned (n = 195, 60% long-term
adopters; n = 38, 79% short-term adopters; n = 184,
90% non-adopters). Long-term adopters had an average
of 34 physicians per hospital prescribing TZDs and initi-
ally adopted TZDs on average 15 months from the time
the drugs were listed by the NBHI. Their average
monthly use of anti-diabetic drugs in the month prior
to TZD’s entry into the market was 37917.47 DDDs.
Their use of TZDs peaked on average to 0.117 (=11.7%)
of all anti-diabetic drugs with mean peak time being
26 months. The mean peak prescription number (maxi-
mum DDD of TZD prescribed) was 6970 DDDs per
month. The monthly growth of TZD prescription num-
bers (i.e., penetration speed) after the introduction was
252 DDDs/month. It took 27 months to for usage to
peak in these long-term adopters. For short-term adop-
ters and non-adopters, the average use of anti-diabetic
drugs in the month immediately before TZD entry were
8468 DDDs and 2243 DDDs, respectively.
Table 2 shows that non-profit hospitals and private
h o s p i t a l sw e r em o r el i k e l yt ob ei n n o v a t o r sa n de a r l y
adopters (OR = 4.12, 95%CI = 1.56 to 10.87; OR = 3.91,
95%CI = 1.64 to 9.36) and early majority (OR = 4.77, 95%
CI = 1.87 to 12.20; OR = 3.38, 95%CI = 1.41 to 8.09) than
public hospitals. Hospitals with higher HHI were less
likely to be innovators and early adopters relative to late
majority and laggards (OR = 0.95, 95%CI = 0.92 to 0.98)
and early majority relative to late majority and laggards
(OR = 0.97, 95%CI = 0.94 to 0.99). Hospitals with larger
prior antidiabetic prescription capacity in log scale were
more likely to be innovators and early adopters relative
to late majority and laggards (OR = 1.93, 95%CI = 1.50 to
2.49) and early majority relative to late majority and lag-
gards (OR = 1.64, 95%CI = 1.30 to 2.08).
Table 3 shows that introduction of TZDs started early
in medical centers (8.28 months after NBHI listing),
non-profit hospitals (12.22 months), and those in the
Taipei region (13.12 months). The peak use was lower
in public hospitals (7.82%) and hospitals in the Northern
region (8.18%). The time lag between initial TZD pre-
scriptions and the peak use was shorter in district hospi-
tals (24.69 months), private hospitals (25.49 months)
and hospitals in the Southern region.
Based on the Cox Proportional Hazards Models, the
adoption of TZDs was negatively associated with phar-
maceutical concentration levels (HR = 0.02, 95% CI =
0.01 to 0.04) (Table 4). District hospitals adopted
TZDs more slowly than medical centers (HR = 0.43,
95%CI = 0.24 to 0.75). Non-profit hospitals adopted
TZD faster the public hospitals (HR = 1.79, 95%CI =
1.23 to 2.61). Hospitals in the Northern (HR = 0.60,
95%CI = 0.41 to 0.89) and Kao-Ping regions (HR =
0.58, 95%CI = 0.41 to 0.82) started prescribing TZDs
later than those in the Taipei region. Most estimates
remained the same in the analysis on TZD adopters,
except in the case of private hospitals, which, after this
analysis, became earlier adopters than public hospitals
(HR = 2.14, 95%CI = 1.49 to 3.06). We checked the
assumption of proportional hazards and they met the
constant proportional hazards assumption (all p-values
were > 0.05). We did not include the number of doc-
tors who prescribed the drug and the economic scale
(log(TDDD.DM) in the final model estimation because
they were highly correlated with the hospital’sa c c r e d i -
tation level.
Results from the quantile regressions showed the dif-
ferential marginal effects of various factors on the pene-
tration speed in different quantiles (Table 5). In three
quantiles, the penetration speed was not significantly
associated with the time lag to adoption of TZD or hos-
pital-level pharmaceutical concentration index. It was,
however, positively associated with prior anti-diabetic
prescription capacity (log(TDDD.DM))a n dt h en u m b e r
of physicians prescribing TZD. The effect of prescription
capacity on penetration speed was larger in the higher
quantiles than lower quantiles (25%Q: 18.29; 50%Q:
25.57; 75%Q: 30.97). The effect of number of physicians
who prescribed TZDs followed a similar pattern (25%Q:
2.65; 50%Q: 3.14; 75%Q: 4.25). Accreditation level was
found to exert a significant effect on penetration speed
in the 50% quantile and 75% quantile, but not in the
25% quantile. In general, regional hospitals (50%Q:
-326.44) and district hospitals (50%Q: -394.48; 75%Q:
-486.58) had slower penetration growth than medical
centers, but not in the 25% quantile. The effects of geo-
graphic region on penetration speed were inconsistent.
In general, hospitals in the eastern regions had slower
pentetration speed than those in other regions, although
this difference was not significant in the 75% quantile.
Private hospitals had significantly higher penetration
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had higher penetration speed than public hospitals
except in the 75% quantile.
Table 6 presents the factors that had significant effects
on peak use across three quantile levels. Longer time lag
between NBHI listing and the first TZD prescription at
a hospital was associated with lower peak use at a hospi-
tal (25%Q: -40.33DDD, 50%Q: -38.65DDD, 75%Q:
-32.29DDD). Peak use was also positively associated
with the speed of TZD prescription increase at a
Table 2 Multinomial logit regression on TZD adoption
innovators and early adopters v.s. late
majority and laggards
early majority v.s. late
majority and laggards
Total OR
2 95% CI OR
2 95% CI
Ownership
Ref: Public Hospital
Non-profit Hospital 4.12 (1.56 10.87) ** 4.77 (1.87 12.2) **
Private Hospital 3.91 (1.64 9.36) ** 3.38 (1.41 8.09) *
BNHI Regions
Ref: Taipei
Northern 0.51 (0.19 1.39) 0.47 (0.18 1.23)
Central 0.85 (0.35 2.06) 0.58 (0.24 1.40)
Southern 1.31 (0.51 3.33) 0.90 (0.36 2.23)
Kao-Ping 0.91 (0.38 2.20) 0.73 (0.32 1.68)
Eastern 0.30 (0.03 2.93) 0.96 (0.22 4.09)
Herfindahl-Hirschman
Indexes
1 (unit: HHI*100)
0.95 (0.92 0.98) ** 0.97 (0.94 0.99) *
log (total DDD of DM in
February, 2001)
1.93 (1.50 2.49) *** 1.64 (1.30 2.08) ***
1: concentration index for hospitals in February, 2001.
2: odds ratio.
***: p < 0.0005 **: p < 0.005 *:p < 0.05.
Table 3 Patterns of adoption and diffusion of TZD in 327 long-term hospitals
Initial time
(month)
Peak
Penetration
1
Time to Peak
(month)
Monthly growth (DDD/
month)
N mean std Mean std mean std mean std
Total number 15.19 11.61 0.1166 0.0667 26.69 13.42 252.65 374.31
Accreditation level
Medical Center 18 8.28 10.31 0.1034 0.0402 34.67 12.25 1275.25 692.43
Regional
Hospital
68 10.97 9.52 0.0985 0.0516 31.68 11.07 410.71 298.44
District Hospital 241 16.90 11.77 0.1227 0.0711 24.69 13.57 131.67 176.87
Ownership
Public Hospital 67 15.94 10.96 0.0782 0.0469 25.63 12.54 302.22 446.00
Non-profit
Hospital
65 12.22 10.18 0.1155 0.0543 31.40 12.45 467.35 513.15
Private Hospital 195 15.93 12.15 0.1302 0.0712 25.49 13.74 164.04 238.14
BNHI Regions
Taipei 78 13.12 9.96 0.1204 0.0657 28.19 13.10 314.77 475.98
Northern 49 16.82 12.21 0.0818 0.0465 23.53 13.52 274.29 397.45
Central 81 16.93 12.21 0.1333 0.0683 26.95 12.85 203.92 284.37
Southern 49 14.08 11.22 0.1164 0.0689 22.90 11.79 294.41 374.88
Kao-Ping 59 15.29 12.86 0.1189 0.0718 28.83 15.56 201.43 328.36
Eastern 11 14.36 8.72 0.1104 0.0566 33.64 8.16 163.19 182.91
1: Peak Penetration among patients receiving non-insulin anti-diabetic agents.
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Page 7 of 13hospital (25%Q: 16.53DDD, 50%Q: 24.91DDD, 75%Q:
31.50DDD). Unlike the scale effect of prescription capa-
city on penetration speed (Table 4), a larger volume of
anti-diabetic prescriptions before TZD introduction was
not associated with TZD peak use. Medical centers had
greater peak use than regional and district hospitals in
the 75% quantile. Non-profit and private hospitals had
higher peak use than the public hospitals across three
quantiles. Hospitals in the northern regions significantly
lower peak use of TZDs than those in the Taipei region
across three quantiles.
Discussion
In this study, we analyzed the diffusion patterns of a
new class of anti-diabetic drugs, TZDs, in the micro-
markets of hospitals across Taiwan, including how
soon hospitals started prescribing these drugs after
they were listed on the national formulary, how quickly
the drugs penetrated each hospital as a small health
care market, and the peak use between March 1, 2001
and December 31, 2005. Our study showed the median
time to adoption was about 15-20 months after formu-
lary listing, and after 50 months, 20 to 40% of hospitals
had still not adopted the drug. The adoption rates
seemed very low. According to our another analyses,
the market share of TZD in the second year after for-
mulary listing was over 5% and in 2005 it was over 7%
[57]. The low adoption rates could possibly be related
to the characteristics of Taiwan health care market
and the reimbursement rules of National Health Insur-
ance. In Taiwan, medical centers have a very high
volume of DM outpatient visits. The Bureau of
National Health Insurance imposes a threshold (ceiling
reimbursement) for each outpatient visit, highest for
medical centers and lowest for the clinics. When the
claim exceeds the threshold, they are reviewed by the
Bureau and are likely to be rejected without proper
justification. In addition, because DM is a chronic dis-
ease, most patients receive 30-day prescriptions of
their DM drugs each time. In order to avoid risk of a
claim being rejected for reimbursement, most clinics
would have had less incentive to prescribe TZD
Table 4 Cox proportional hazards models on initial time of adoption of TZD Unit:(month)
580 hospitals (total) initial
time to adoption of TZD
(month)
327 hospitals (adopters only)
initial time to adoption of TZD
(month)
HR
1 95% CI p-value HR
1 95% CI p-
value
HHI in February,
2001 (unit:
HHI*100)
0.02 (0.01 0.04) 0.0000 *** 0.07 (0.03 0.18) 0.0000 ***
Accreditation level
ref: Medical
Center
Regional
Hospital
0.75 (0.43 1.32) 0.3000 1.01 (0.56 1.81) 0.9700
District
Hospital
0.43 (0.24-0.75) 0.0024 ** 0.53 (0.3 0.94) 0.0260 *
BNHI Regions
Ref: Taipei
Northern 0.6 (0.41 0.89) 0.0090 * 0.65 (0.44 0.96) 0.0280 *
Central 0.88 (0.63 1.23) 0.4500 0.82 (0.58 1.14) 0.2300
Southern 0.75 (0.52 1.09) 0.1200 0.83 (0.57 1.21) 0.3300
Kao-Ping 0.58 (0.41 0.82) 0.0015 ** 0.98 (0.69 1.4) 0.9200
Eastern 0.69 (0.37 1.27) 0.2300 0.7 (0.37 1.32) 0.2600
Ownership
ref: Public
Hospital
Non-profit
Hospital
1.79 (1.23 2.61) 0.0019 ** 1.87 (1.26 2.78) 0.0015 **
Private
Hospital
1.35 (0.94 1.94) 0.0950 2.14 (1.49 3.06) 0.0000 ***
1: hazard ratio; HR < 1 means the factor inhibited adoption and an HR > 1 means the factor accelerated adoption.
***: p < 0.0005 **: p < 0.005 *:p < 0.05.
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Page 8 of 13because its unit price was much higher than the unit
prices of the other oral antidiabetic agents. Neverthe-
less, most importantly, our study showed that health
care provider characteristics presented a potential
access barrier to new drug for Type II DM in Taiwan.
We found that the market penetration of TZDs varied
substantially by individual hospital characteristics, such
as a hospital’s prior pharmaceutical structure, accredita-
tion level, and ownership type. The adoption of the new
drug class TZDs in a hospital was highly correlated with
the hospital’s prior pharmaceutical structure (measured
by modified Herfindahl-Hirschman Index). Although the
statistics of our modified HHI cannot be interpreted
directly according to general threshold, they indicate to
some extent the pattern of market structure of anti-dia-
betic drugs in Taiwan. Our study showed that early
adoption was more likely if the physicians in a particular
hospital were in the habit of prescribing multiple anti-
diabetic drugs for their patients. This prescribing pattern
was also associated with shorter time lag between adop-
tion and new drug availability. The rate of growth of
TZDs in a hospital was influenced by the hospital’se c o -
nomic scale of anti-diabetic drugs and the number of
physicians prescribing TZDs. The speed of TZD pene-
tration was not significantly associated with how quickly
a hospital adopted TZDs. These findings indicate that
Table 5 Quantile regressions on monthly growth of TZD prescriptions, (n = 327 long-term adopters)
Speed of TZD
prescription
(Monthly Growth
on Total DDD of
TZD)
Speed of TZD
prescription
(Monthly Growth
on Total DDD of
TZD)
Speed of TZD
prescription
(Monthly Growth
on Total DDD of
TZD)
25% quantile 50% quantile 75% quantile
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
Intercept 57.14 (-73.90 149.35) 143.87 (-125.85 474.82) 248.98 (-142.24 1045.51)
Initial time to
adoption of TZD
in month
0.60 (-0.17 0.99 ) 0.47 (-0.81 0.82) 0.13 (-0.57 1.86)
log (total DDD of
DM in February,
2001)
18.29 (12.14 27.75) * 25.57 (14.74 34.87) * 30.97 (17.17 40.80) *
HHI in February,
2001(unit:
HHI*100)
-7.88 (-55.35 45.67) 10.81 (-78.56 90.25) 67.73 (-46.51 180.98)
Number of
doctors who
prescribed TZD
2.65 (0.71 4.49 ) * 3.14 (1.44 5.20) * 4.25 (1.19 6.30) *
Accreditation
level
Ref: Medical
Center
Regional
Hospital
-193.39 (-355.21 396.19) -326.44 (-577.59 -35.84) * -295.57 (-962.53 159.11)
District
Hospital
-249.47 (-410.38 451.57) -394.48 (-647.42 -101.94) * -486.58 (-1351.85 -32.69) *
NHI Regions
Ref: Taipei
Northern -20.33 (-30.27 -1.70) * -23.94 (-58.11 52.29) -11.05 (-93.18 51.03)
Central 2.85 (-4.73 15.90) 18.64 (-34.77 49.89) -40.12 (-89.09 -2.39) *
Southern 6.93 (-10.92 20.61) 7.90 (-23.38 45.70) -22.49 (-67.47 119.84)
Kao-Ping -4.05 (-18.10 10.18 ) 2.64 (-37.65 32.81) -69.48 (-112.26 -16.17) *
Eastern -38.15 (-60.45 -27.91) * -71.45 (-104.30 -50.74) * -114.75 (-171.58 - 36.97)
Ownership
Ref: Public
Hospital
Non-profit
Hospital
74.52 (42.13 95.49) * 103.08 (30.75 130.09) * 73.89 (-0.08 145.26)
Private
Hospital
53.95 (30.05 71.65) * 66.10 (12.52 91.35) * 77.15 (37.58 112.26) *
*: the 95% confident interval doesn’t contain zero.
Wen et al. BMC Health Services Research 2011, 11:21
http://www.biomedcentral.com/1472-6963/11/21
Page 9 of 13the rate of market penetration was largely determined
by prescription capacity and the herding effect. Peak use
was, in contrast, influenced by how quickly hospitals
adopted TZDs but not prescription capacity. In addition,
faster penetration speed was linked to higher peak use.
Our results indicated that the adoption and diffusion
of new TZDs was highly associated with accreditation
level and hospital ownership (Figure 2). Medical centers
tended to adopt the new drugs earlier than the other
hospitals. In Taiwan, medical centers have a high
volume of outpatient visits and low concentration HHIs.
Their relatively large prescription volumes may be one
reason medical centers were more likely to prescribe
new drugs. Another possible explanation is that pharma-
ceutical industry targets medical centers the most for
promotion because of the large volume of anti-diabetic
prescriptions at these institutions.
Medical centers and other high-volume hospitals had
a lower peak use (10.34%) than other types of hospitals.
This finding demonstrates that, although a less-concen-
trated market is easier to enter, new drugs may still
face intense internal competition within the hospital,
especially if they are not a new and unique treatment
for a disease. Because the BNHI regularly analyzes drug
expenditure data, hospitals that spend more on medica-
tions, including medical centers that care for patients
with more severe diseases, are pressured to cut costs
and prescribe less expensive drugs. In addition, it is
possible that new drugs had been used in the medical
centers. These centers are sometimes involved in clini-
cal studies of drugs that yet to be listed on BNHI
formulary. These medical centers may, therefore, be
much faster to adopt new drugs because of their prior
experience.
Table 6 Quantile regressions on peak monthly TZD prescriptions in DDD, (n = 327 long-term adopters)
Peak
Monthly
Prescriptions
in DDD
Peak
Monthly
Prescriptions
in DDD
Peak
Monthly
Prescriptions
in DDD
25% quantile 50% quantile 75% quantile
Coefficient 95% CI Coefficient 95% CI Coefficent 95% CI
Intercept -11683.46 (-25849.01 4891.88) 3087.64 (-1755.33 9708.63) 6092.86 (3040.05 13060.79) *
Initial time to adoption
of TZD in month
-40.33 (-90.40 -21.74) * -38.65 (-60.14 -18.79) * -32.29 (-40.34 -25.03) *
log (total DDD of DM in
February, 2001)
144.32 (-23.53 501.21) 63.94 (-103.01 252.24) -7.11 (-134.58 55.07)
Number of doctors who
prescribed TZD
56.75 (-0.63 128.80) 41.67 (23.84 71.43) * 35.51 (14.66 104.83) *
Prescription Speed
(monthly growth on
TZD prescription; DDD/
month)
16.53 (10.99 18.80 ) * 24.91 (20.61 28.60) * 31.50 (28.04 35.07) *
Accreditation level
Ref: Medical Center
Regional Hospital 9572.52 (-9434.71 21541.35) -3241.95 (-8473.35 4505.39) -5666.94 (-20463.60 -1502.91) *
District Hospital 8507.36 (-11661.53 22343.97) -3801.32 (-9289.80 2804.17) -5868.08 (-13770.06 -1838.18) *
NHI Regions
Ref: Taipei
Northern -1017.83 (-1835.78 -547.86) * -866.80 (-1422.52 -133.63) * -451.32 (-625.48 -233.11) *
Central 70.82 (-410.31 368.95) -95.32 (-304.72 272.10) -28.60 (-251.57 172.36)
Southern -487.75 (-1144.62 -11.28) * -495.10 (-1015.13 -54.84) * -451.29 (-842.53 -2.09) *
Kao-Ping -69.25 (-839.40 553.97) 179.82 (-143.65 823.57) 507.19 (105.50 1048.41) *
Eastern 497.82 (-405.36 1013.11) -63.27 (-652.49 235.63) -375.01 (-651.40 -28.58) *
Ownership
Ref: Public Hospital
Non-profit Hospital 2478.04 (1309.10 5472.91) * 1081.43 (497.90 1751.43) * 725.85 (321.59 987.01) *
Private Hospital 2521.98 (1138.68 4492.53) * 872.32 (344.70 1456.89) * 391.32 (159.27 658.54) *
*: the 95% confident interval doesn’t contain zero.
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Page 10 of 13With regard to ownership types, public hospitals were
slower to adopt TZDs than non-profit and private hos-
pitals and had lower rates of increase and peak number
of prescriptions for TZDs. Public hospitals’ low pharma-
ceutical concentration index did not facilitate the new
drug entry into this market sector. This phenomenon is
worthy of further investigation because public hospitals
are different from non-profit and private hospitals in
several ways. First, many public hospitals are subject to
more restrictive policies and regulations such as collec-
tive bargaining. New drugs may not easily enter a public
hospital without the agreement from other hospitals in
the same alliance. The purchasing committees are com-
posed of physicians and staff coming from different hos-
pitals and backgrounds and may take some time to
reach consensus on adopting new drugs into the collec-
tive purchase list. Second, public hospitals receive finan-
cial subsidies from the government and their staff
members are government employees paid set salaries.
These physicians have less financial incentive to pre-
scribe expensive medicine, unlike physicians in private
hospitals who may have gained directly or indirectly
through increased prescribing of new drugs.
Most research on diffusion of technology has assumed
that consumers are homogenous in their consumption
behavior. This approach does not provide a comprehen-
sive picture of market penetration. Many factors may
influence how new drugs are adopted and diffused into
a market, but research in these areas are lacking. Our
study examined the diffusion patterns of new drugs into
hospitals with various characteristics. The insights
gained in this study can be used to predict market pene-
tration in different types of hospitals and provide infor-
mation regarding short-term and medium-term drug
utilization and healthcare cost projections.
This study has some limitations. It lacks information
on the margin between reimbursed price and pharma-
ceutical procurement cost, which hinders the possibility
of exploring the potential association between financial
incentive and diffusion of new drugs. In addition, we
combined all anti-diabetic drugs and both TZDs
together in analyses, which may have glossed over nota-
ble clinical differences among all the drugs. On the
other hand, because TZDs are chronically administered
drugs, total claims will represent a mixture of new starts
and refills with refills becoming the predominant share
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Figure 2 The diffusion pattern of new DM drug among hospitals in Taiwan.
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Page 11 of 13over time. Therefore, in fact, we were modeling peak
use of total prescription “consumption” not penetration
of the patient market in each hospital. Future analyses
could be strengthened if they differentiate between new
starts versus refills and take into account the patient
mix. Undoubtedly, certain omitted factors, especially
health-related policy interventions or events, may have
influenced prescribing trends and confounded our esti-
mates. For instance, our estimate on the adoption and
the growth of prescription could be affected when NHI
implemented price-cuts on pharmaceuticals. Finally, in
order to analyze the diffusion pattern of the new drugs,
our study excluded those health care providers which
had very small volume of DM prescription. Thus, it is
would limit generalization of our conclusion to the
whole health care market. Our study cannot also be
generalized to the diffusion pattern of health technology.
Conclusions
In summary, our study shows that hospitals, when
considered pharmaceutical micro-markets, differs sub-
stantially in their adoption and diffusion of a new drug
class, TZDs, to treat type 2 diabetes. This finding sug-
gests that the diffusion of new drugs is associated with
non-medical factors regardless of their incremental
therapeutic benefits or unexpected adverse reactions.
In the past few years, studies on TZD have raised con-
cerns about fluid retention and increased risk of heart
failure [58-62]. Two randomized clinical trials, the
DREAM trial [63] and the PROactive study [64], have
found TZD to slightly increase the risk of heart failure.
A recently published meta-analysis by Nissen and
Wolski [65] has additionally raised concerns that TZD
may also increase the risk of myocardial infarction in
diabetic patients. This led to an FDA public health
advisory. Given the high profile safety discussions for
this class of drugs, it would be worthwhile to study the
“un-adoption” of drugs following drug warnings.
Therefore, future research could examine when and
h o wd i f f u s i o no fn e wd r u g si sdesired or beneficial to
the public.
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